BioNTech SE Long Term Debt 2019-2025 | BNTX

BioNTech SE long term debt for the quarter ending March 31, 2025 was $0.250B, a 12.42% increase year-over-year.

  • BioNTech SE long term debt for 2024 was $0.232B, a 12.39% increase from 2023.
  • BioNTech SE long term debt for 2023 was $0.207B, a 11.35% increase from 2022.
  • BioNTech SE long term debt for 2022 was $0.186B, a 8.56% decline from 2021.

BioNTech SE Long Term Debt 2019-2025 | BNTX

  • BioNTech SE long term debt for 2024 was $0.232B, a 12.39% increase from 2023.
  • BioNTech SE long term debt for 2023 was $0.207B, a 11.35% increase from 2022.
  • BioNTech SE long term debt for 2022 was $0.186B, a 8.56% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$218.6B
Amgen (AMGN)$164.4B
Gilead Sciences (GILD)$137B
Vertex Pharmaceuticals (VRTX)$120.7B
Bristol Myers Squibb (BMY)$97.7B
CSL (CSLLY)$84.2B
GSK (GSK)$75.8B
Regeneron Pharmaceuticals (REGN)$60.6B
Alnylam Pharmaceuticals (ALNY)$42.4B
Argenex SE (ARGX)$35B
Royalty Pharma (RPRX)$20.3B
Insmed (INSM)$19.5B
Biogen (BIIB)$18.7B
Illumina (ILMN)$16.2B
Genmab (GMAB)$14B
Genmab (GNMSF)$13.8B
Incyte (INCY)$13.3B
Moderna (MRNA)$12.7B
Exelixis (EXEL)$12.1B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$11B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.1B
Exact Sciences (EXAS)$9.4B
Verona Pharma American Depositary Share (VRNA)$8.9B
Blueprint Medicines (BPMC)$8.3B
Bio-Techne Corp (TECH)$8.3B
Legend Biotech (LEGN)$8.1B
Roivant Sciences (ROIV)$7.8B
Revolution Medicines (RVMD)$7.1B